Accelerating research

and development of

new antibiotics and


The Netherlands Antibiotic Development Platform

The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.

NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.

Stay informed on NADP and subscribe to our Update.

NADP Vouchers

An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.

These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.

Latest News

2021 Antimicrobial Resistance Benchmark report

The third AMR Benchmark is an independent report that compares and analyses how pharmaceutical companies are responding to the crisis of antimicrobial resistance.


Join the next GARDP AMR discussion 19th November

This World Antimicrobial awareness week, GARDP, together with WHO, will be holding an AMR Discussions webinar. A panel will discuss the roles that different actors can play in the development of new antibiotics.


Media-attention for AMR: “Create anti-bodies to strengthen bodies’ defences.”

For the Dutch radio program at NPO radio 1, Suzan Rooijakkers, explains how Antimicrobial Resistance (AMR) continues to threaten our abilities to treat common infections.


NADP Partners

Supported by

NADP Partners

Supported by